A study of the PAN-KRAS inhibitor LY4066434 in participants with KRAS mutant solid tumors.
J5Q-OX-JRDA
Phase 1 other active
Quick answer
A study of the PAN-KRAS inhibitor LY4066434 in participants with KRAS mutant solid tumors. for Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor Metastatic Solid Tumor, PanKRAS. is a Phase 1 program (other) at Eli Lilly Co. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eli Lilly Co.
- Indication
- Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor Metastatic Solid Tumor, PanKRAS.
- Phase
- Phase 1
- Modality
- other
- Status
- active